A detailed history of Parallel Advisors, LLC transactions in Vericel Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 335 shares of VCEL stock, worth $18,991. This represents 0.0% of its overall portfolio holdings.

Number of Shares
335
Previous 340 1.47%
Holding current value
$18,991
Previous $15,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.25 - $53.56 $211 - $267
-5 Reduced 1.47%
335 $14,000
Q2 2024

Aug 08, 2024

BUY
$41.71 - $52.9 $208 - $264
5 Added 1.49%
340 $15,000
Q4 2023

Feb 09, 2024

BUY
$30.85 - $37.09 $10,334 - $12,425
335 New
335 $11,000
Q2 2022

Aug 01, 2022

BUY
$22.88 - $39.45 $2,082 - $3,589
91 Added 313.79%
120 $3,000
Q1 2022

Apr 28, 2022

BUY
$31.69 - $43.29 $285 - $389
9 Added 45.0%
29 $1,000
Q2 2021

Aug 06, 2021

SELL
$47.2 - $67.81 $1,746 - $2,508
-37 Reduced 64.91%
20 $1,000
Q1 2021

Apr 23, 2021

BUY
$30.93 - $59.48 $1,763 - $3,390
57 New
57 $3,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.67B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.